Assessment of the Coronary Artery Disease and Systolic Dysfunction in Hypertensive Patients with the Dobutamine-Atropine Stress Echocardiography: Effect of the Left Ventricular Hypertrophy

Cardiology ◽  
1997 ◽  
Vol 89 (1) ◽  
pp. 52-58 ◽  
Author(s):  
Yi-Lwun Ho ◽  
Chau-Chung Wu ◽  
Lung-Chun Lin ◽  
Chien-Hua Huang ◽  
Wen-Jone Chen ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Left Ventricular Hypertrophy ◽  
Stress Echocardiography ◽  
Ventricular Hypertrophy ◽  
Systolic Dysfunction ◽  
Left Ventricular ◽  
Hypertensive Patients ◽  
Artery Disease

Lack of increased left main coronary artery dimensions in hypertensive patients with left ventricular hypertrophy and coronary artery disease

2004 ◽  
Vol 59 (4) ◽  
pp. 397-403
Author(s):  
Manolis VAVURANAKIS ◽  
Agelos RIGOPOULOS ◽  
Sofia VAINA ◽  
Christina CHRYSOHOOU ◽  
Konstantinos TOUTOUZAS ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Left Main Coronary Artery ◽  
Left Ventricular ◽  
Left Main ◽  
Hypertensive Patients ◽  
Artery Disease

scholarly journals Influence of Exercise on QT Dispersion in Hypertensive Patients With Left Ventricular Hypertrophy Without Coronary Artery Disease

1999 ◽  
Vol 63 (11) ◽  
pp. 881-884 ◽  
Author(s):  
Mitsuisa Yoshimura ◽  
Koji Matsumoto ◽  
Mitsuaki Watanabe ◽  
Naoko Yamashita ◽  
Eiko Sanuki ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Qt Dispersion ◽  
Left Ventricular ◽  
Hypertensive Patients ◽  
Artery Disease

scholarly journals A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial

2019 ◽  
Vol 40 (41) ◽  
pp. 3409-3417 ◽  
Author(s):  
Mohapradeep Mohan ◽  
Shaween Al-Talabany ◽  
Angela McKinnie ◽  
Ify R Mordi ◽  
Jagdeep S S Singh ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Coronary Artery Disease ◽  
Body Weight ◽  
Coronary Artery ◽  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Haemoglobin A1c ◽  
Metformin Treatment ◽  
Artery Disease

Abstract Aim We tested the hypothesis that metformin may regress left ventricular hypertrophy (LVH) in patients who have coronary artery disease (CAD), with insulin resistance (IR) and/or pre-diabetes. Methods and results We randomly assigned 68 patients (mean age 65 ± 8 years) without diabetes who have CAD with IR and/or pre-diabetes to receive either metformin XL (2000 mg daily dose) or placebo for 12 months. Primary endpoint was change in left ventricular mass indexed to height1.7 (LVMI), assessed by magnetic resonance imaging. In the modified intention-to-treat analysis (n = 63), metformin treatment significantly reduced LVMI compared with placebo group (absolute mean difference −1.37 (95% confidence interval: −2.63 to −0.12, P = 0.033). Metformin also significantly reduced other secondary study endpoints such as: LVM (P = 0.032), body weight (P = 0.001), subcutaneous adipose tissue (P = 0.024), office systolic blood pressure (BP, P = 0.022) and concentration of thiobarbituric acid reactive substances, a biomarker for oxidative stress (P = 0.04). The glycated haemoglobin A1C concentration and fasting IR index did not differ between study groups at the end of the study. Conclusion Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress. Although LVH is a good surrogate marker of cardiovascular (CV) outcome, conclusive evidence for the cardio-protective role of metformin is required from large CV outcomes trials.

Sign in / Sign up

Export Citation Format

Share Document